Globus Medical to acquire NuVasive in $3.1B all-stock merger; 0.75 exchange ratio

GLOBUS MEDICAL INC

Exchange ratio: 0.75 GMED shares per NUVA share; implied price $57.72; equity value $3.1B.
Combined ownership: GMED shareholders 72%, NUVA shareholders 28% on fully diluted basis.
Expects mid-30% EBITDA margin in 3 years and ~$170M in identified cost synergies.
Dan Scavilla to remain CEO; Chris Barry to support integration; board expands to 11 (3 from NuVasive).
Transaction expected to close mid-2023, subject to shareholder and regulatory approvals.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

GLOBUS MEDICAL INC reported preliminary financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On February 9, 2023, Globus Medical, Inc. (“Globus Medical” or the “Company”) issued the Joint Press Release (as defined in Item 7.01 below) which contained certain preliminary financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-23-029211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.